21 Apr 2016 07:00
BEXIMCO PHARMACEUTICALS LTD.
21st April, 2016
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Ltd. ("BPL", "Beximco Pharma" or "Company"), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 20th April, 2016 has decided the following:
1. | To recommend the approval of the Financial Statements for the year ended 31 December 2015 | : | The Audited Financial Statements for the year ended 31 December 2015 has been approved. The full accounts are expected to be announced by 4th May 2016 |
2. | Date & Time of 40th AGM of the Company for the year 2015 | : | 4 June, 2016 at 10.30 am |
3. | Venue of AGM | : | Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh |
4. | Proposed Dividend for the year ended 31 December 2015 | : | 5% Stock Dividend (i.e. 5 shares for every 100 shares held) and 10% Cash Dividend (i.e. Tk. 1 per share) |
5. | Record date | : | 12 May, 2016 |
6. | Net Asset Value as at 31 December 2015 | : | Taka 22,478,627,583 |
7. | Net Asset Value per Share as at 31 December 2015 | : | Taka 58.20 |
8. | Earnings per share (EPS) for the year ended 31 December 2015 | : | Taka 5.06 |
9. | Net Operating Cash Flow per share for the year ended 31 December 2015 | : | Taka 4.75 |
For further information please visit www.beximco-pharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films, etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of the US, Australia, Europe, Latin America and Canada, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific Island; Latin and Central American countries; Middle East; Central Asia; South East Asia, including Singapore, Malaysia, Indonesia, Philippines and Hong Kong; Europe, including Germany, Austria and Romania; Australia etc.
Beximco Pharma (BXP)